The measurement of SARS-CoV-2-specific antibodies was performed using the Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, Basel, Switzerland). This semiquantitative electrochemiluminescence immunoassay measures SARS-CoV-2 nucleocapsid-specific IgG. The assay was performed by the South African National Health Laboratory Service and interpreted according to the manufacturer's instructions (Roche: version 1.0 2020-05). Results are reported as numeric values in the form of a cut-off index (COI) (signal sample/cut-off), where a COI <1.0 corresponds to nonreactive plasma and a COI ⩾1.0 corresponds to reactive plasma. At 14 days post-SARS-CoV-2 PCR confirmation, the sensitivity and specificity of the Elecsys Anti-SARS-CoV-2 immunoassay has been reported as 99.5% (95% CI 97.0–100.0%) and 99.80% (95% CI 99.69–99.88%), respectively [10 (link)–12 (link)].